By Joe Cintavey
Published in: Cell & Gene
Published on: November 7, 2022
Conclusion: As manufacturers develop more advanced therapeutics, especially cell and gene therapies, solutions that support reliable cold chains will become central. Biopharmaceuticals culminate in complex design decisions requiring substantial research, resources, and time investment.
Oftentimes, manufacturers will misguidedly look to improve end-user training and secondary packaging before first evaluating the most durable primary solutions to prevent product loss. Many recognize the critical aspect and value, both in cost and to patients, of container integrity. The key takeaway for manufacturers is that by choosing the most durable and innovative primary packaging, they can eliminate potential issues that might occur through subsequent phases of supply chain transportation.
